Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutikizumab + ravagalimab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
This drug is an **experimental combination therapy** of two monoclonal antibodies, **lutikizumab** and **ravagalimab**, designed for immunomodulation in inflammatory diseases. Lutikizumab is a dual-variable-domain monoclonal antibody that antagonizes both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), targeting pathways implicated in various inflammatory and autoimmune diseases[1][3][6][9]. Ravagalimab is a fully humanized monoclonal antibody that functions as a CD40 antagonist by stabilizing and preventing the activation of the CD40 receptor, thereby suppressing pro-inflammatory immune responses[2][5]. The combination is being evaluated in Phase 2 clinical trials for **moderately to severely active rheumatoid arthritis** in patients who failed previous biologic/tsDMARD therapy. Both drugs are under development by AbbVie[4][7][10].
- Other names
- lutikizumab + ravagalimab
02
Targets
CD40 (Cluster of differentiation 40 receptor)IL1A (Interleukin 1 alpha)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on lutikizumab + ravagalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutikizumab + ravagalimab.